Article

Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis

The Osteoporosis Clinic, Department of Endocrinology and Metabolism C, Aarhus University Hospital Aarhus Amtssygehus, Tage Hansens Gade 2, 8000 Aarhus C, Denmark.
Osteoporosis International (Impact Factor: 4.17). 03/2008; 19(3):257-68. DOI: 10.1007/s00198-007-0437-6
Source: PubMed

ABSTRACT Fluoride has fallen into discredit due to the absence of an anti-fracture effect. However, in this meta-analysis, a fracture reducing potential was seen at low fluoride doses [< or =20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride)]: OR = 0.3, 95% CI: 0.1-0.9 for vertebral and OR = 0.5, 95% CI: 0.3-0.8 for non-vertebral fractures.
Fluoride is incorporated into bone mineral and has an anabolic effect. However, the biomechanical competence of the newly formed bone may be reduced.
A systematic search of PubMed, Embase, and ISI web of science yielded 2,028 references.
Twenty-five eligible studies were identified. Spine BMD increased 7.9%, 95% CI: 5.4-10.5%, and hip BMD 2.1%, 95% CI: 0.9-3.4%. A meta-regression showed increasing spine BMD with increasing treatment duration (5.04 +/- 2.16%/year of treatment). Overall there was no significant effect on the risk of vertebral (OR = 0.8, 95% CI: 0.5-1.5) or non-vertebral fracture (OR = 0.8, 95% CI: 0.5-1.4). With a daily dose of < or =20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride), there was a statistically significant reduction in vertebral (OR = 0.3, 95% CI: 0.1-0.9) and non-vertebral (OR = 0.5, 95% CI: 0.3-0.8) fracture risk. With a daily dose >20 mg fluoride equivalents, there was no significant reduction in vertebral (OR = 1.3, 95% CI: 0.8-2.0) and non-vertebral (OR = 1.5, 95% CI: 0.8-2.8) fracture risk.
Fluoride treatment increases spine and hip BMD, depending on treatment duration. Overall there was no effect on hip or spine fracture risk. However, in subgroup analyses a low fluoride dose (< or =20 mg/day of fluoride equivalents) was associated with a significant reduction in fracture risk.

0 Bookmarks
 · 
162 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporotic fractures are common and result in extensive morbidity and mortality. It is possible to decrease the risk of fracture in postmenopausal, male, and glucocorticoid-induced osteoporosis with appropriate screening and treatment. The assessment of fracture risk, for which bone densitometry is only 1 component, should be the main focus of patient evaluation. Epidemiologically derived risk-assessment tools such as World Health Organization Fracture Risk Assessment Tool (FRAX) provide physicians with a way to determine the 10-year risk of osteoporotic fracture and effectively choose candidates for therapy. A number of potent skeletal antiresorptive and anabolic drugs have become available to treat osteoporosis and prevent up to 70% of fractures. Here, we provide a detailed update on clinical osteoporosis, the contribution of bone densitometry, and the approach to patients using risk assessment in the consideration of treatments. Progress in osteoporosis is an example of successful bench-to-bedside research benefitting populations worldwide.
    Seminars in Nuclear Medicine 11/2014; 44(6):439-450. DOI:10.1053/j.semnuclmed.2014.06.006 · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of observational studies in informing clinical practice is debated, and high profile examples of discrepancies between the results of observational studies and randomised controlled trials (RCTs) have intensified that debate. We systematically reviewed findings from the Nurses' Health Study (NHS), one of the longest and largest observational studies, to assess the number and strength of the associations reported and to determine if they have been confirmed in RCTs.
    PLoS ONE 10/2014; 9(10):e110403. DOI:10.1371/journal.pone.0110403 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis, an increasing public health problem in Poland and all over the world, is characterized by reduced bone mineral mass. As the demographic shift to a more aged population continues, a growing number of men and women will be afflicted with osteoporosis. Seventy one and a half million of Americans will be 65, and nine million and six hundred thousands of Poles will be in 60-65 years of age in 2030. In general osteoporosis is connected with women health, although recently an increasing number of cases in men is observed. According to statistic, about 25% of women and 13% of men over 60 years of age suffer from osteoporosis in Poland. This review shows the findings of the studies to date which examine the role of the oxidative stress, plants, elements and physical activity for the prevention and treatment of osteoporosis.

Full-text (2 Sources)

Download
73 Downloads
Available from
May 17, 2014